相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway
J. Zhou et al.
LEUKEMIA (2008)
(R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1
Thomas Perrotton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with mcl-1 and cFLIPL down-regulation
Roberto R. Rosato et al.
CANCER RESEARCH (2007)
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations
Rama Krishna Kancha et al.
EXPERIMENTAL HEMATOLOGY (2007)
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations
Hitoshi Kiyoi et al.
CLINICAL CANCER RESEARCH (2007)
被撤回的出版物: Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve mcl-1 and p21CIP1 down-regulation(Retracted article. See vol.22, pg.4959,2016)
Girija Dasmahapatra et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)
A. Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia
Deepa B. Shankar et al.
BLOOD (2007)
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D. Auclair et al.
LEUKEMIA (2007)
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
Ming Zhao et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2007)
The ability of sorafenib to inhibit oncogenic PDGFR beta and FLT3 mutants and overcome resistance to other small molecule inhibitors
Els Lierman et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Pgp and FLT3: Identification and modulation of two proteins that lead to chemotherapy resistance in acute myeloid leukemia
Janos Kappelmayer et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring F10-activating mutations
Uichi Nishiyama et al.
LEUKEMIA RESEARCH (2006)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
Barbara Wassmann et al.
BLOOD (2006)
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro:: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways
Chunrong Yu et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner
P. Brown et al.
LEUKEMIA (2006)
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Shem Patyna et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia
ZH Zeng et al.
CANCER RESEARCH (2006)
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
DH Albert et al.
MOLECULAR CANCER THERAPEUTICS (2006)
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia:: A phase II study by the Japan Adult Leukemia Study Group
M Yanada et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation
M Rahmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
FLT3 tyrosine kinase inhibitors
M Levis et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
M Levis et al.
BLOOD (2005)
CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia
DEL de Menezes et al.
CLINICAL CANCER RESEARCH (2005)
Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase
Y Komeno et al.
LEUKEMIA (2005)
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
KT Kim et al.
BLOOD (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins
B Scheijen et al.
ONCOGENE (2004)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors
HM Hunter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)
In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia
O Kretz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
KWH Yee et al.
BLOOD (2004)
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
DA Thomas et al.
BLOOD (2004)
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis
IJ Griswold et al.
BLOOD (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man
D McKillop et al.
XENOBIOTICA (2004)
Natural history and functional divergence of protein tyrosine kinases
JY Gu et al.
GENE (2003)
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines
IA Avramis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3)
K Murata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3:: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells
E Sitnicka et al.
BLOOD (2003)
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
FJ Giles et al.
BLOOD (2003)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit
A Gazit et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
J Sohal et al.
BLOOD (2003)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
M Mizuki et al.
BLOOD (2003)
A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571
FD Böhmer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
KWH Yee et al.
BLOOD (2002)
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy
N Boissel et al.
LEUKEMIA (2002)
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family
A Pandey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
LM Kelly et al.
CANCER CELL (2002)
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain
H Kiyoi et al.
ONCOGENE (2002)
Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase
S Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
AF List et al.
BLOOD (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Theme and variations: Juxtamembrane regulation of receptor protein kinases
SR Hubbard
MOLECULAR CELL (2001)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2001)
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
DL Stirewalt et al.
BLOOD (2001)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
Y Kano et al.
BLOOD (2001)
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
DJ Propper et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2001)
Alpha-1-acid glycoprotein
T Fournier et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY (2000)
FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
SL Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
WJC Rombouts et al.
LEUKEMIA (2000)
分享论文
